MLICM
MRNS

Metropolitan Life Insurance Company (MetLife)’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,731
Closed -$24.7K – 2282
2024
Q1 		$24.7K Hold
2,731
– – ﹤0.01% 1755
2023
Q4 		$29.7K Hold
2,731
– – ﹤0.01% 1726
2023
Q3 		$22K Hold
2,731
– – ﹤0.01% 1846
2023
Q2 		$29.7K Buy
+2,731
New +$23.4K ﹤0.01% 1723
2022
Q2 		– Sell
-2,539
Closed -$23.7K – 2452
2022
Q1 		$23.7K Sell
2,539
-3,581
-59% -$35.6K ﹤0.01% 2011
2021
Q4 		$72.7K Sell
6,120
-667
-10% -$7.7K ﹤0.01% 2623
2021
Q3 		$77.2K Sell
6,787
-4,049
-37% -$55.7K ﹤0.01% 2656
2021
Q2 		$194K Buy
10,836
+3,578
+49% +$57.6K ﹤0.01% 2160
2021
Q1 		$112K Sell
7,258
-949
-12% -$13.7K ﹤0.01% 2372
2020
Q4 		$100K Hold
8,207
– – ﹤0.01% 2359
2020
Q3 		$105K Buy
8,207
+678
+9% +$5.85K ﹤0.01% 2188
2020
Q2 		$76.5K Buy
+7,529
New +$69.3K ﹤0.01% 2402
2018
Q4 		– Sell
-3,382
Closed -$135K – 2580
2018
Q3 		$135K Buy
+3,382
New +$96.2K ﹤0.01% 2268

Other funds holding MRNS

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s MRNS Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2024, closing a stake of 2,731 shares — an estimated $24.7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in MRNS in Q3 2018 and held it in 13 quarters. The position peaked at $194K in Q2 2021. 90 funds tracked by Wall St. Rank hold MRNS as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,731 Marinus Pharmaceuticals, Inc shares in Q2 2024, an estimated $24.7K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Marinus Pharmaceuticals, Inc in Q3 2018 and held it in 13 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Marinus Pharmaceuticals, Inc position peaked at $194K in Q2 2021.
  • 90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.